Sodium valproate in schizophrenia: some biochemical correlates.
Sodium valproate given in doses of 750-3000 mg daily to eight schizophrenic patients produced a qualitatively similar increase in symptoms in five. CSF showed no significant change in gamma-amino-butyric acid or methoxy hydroxyphenyl glycol, but homovanillic acid increased non-significantly in five patients.
D000328:Adult; D002986:Clinical Trials as Topic; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D008875:Middle Aged; D012559:Schizophrenia / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D014635:Valproic Acid / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000134:cerebrospinal fluid
D008734:Methoxyhydroxyphenylglycol; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D006719:Homovanillic Acid